Personalis, Inc. (NASDAQ: PSNL) has unveiled breakthrough clinical data showing its NeXT Personal ctDNA blood test can ...

From antibody-drug conjugates to PARP inhibitors, innovative treatments are offering new hope for patients with ...

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...

CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...

Effect of multifunctional biocatalytic nanoenzyme AuC@SCOF-Mn on photodynamic-immunoactivation cascade response and antitumor efficacy in triple negative breast cancer. This is an ASCO Meeting ...

The data may change how patients are treated following a diagnosis for advanced triple-negative breast cancer, one expert ...

Study presented at ESMO Breast 2025 finds specific gut bacteria and microbial enzymes may be linked to breast cancer ...

Personalis, Inc. , a leader in advanced genomics for precision oncology, announced the presentation of new clinical results from the PREDICT DNA and SCANDARE studies highlighting the capabilities of ...

Researchers at the University of Glasgow have received £399,670 in funding from Breast Cancer Now and Secondary1st to develop ...

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the completion of enrollment in the Phase ...

Trodelvy and Keytruda combination shows promise in treating advanced triple-negative breast cancer, improving ...